NCT05372692View on ClinicalTrials.gov

Study of LD013 in Subjects With Refractory or Relapsed Mesothelin -Positive Ovarian Cancer

NACompletedINTERVENTIONAL
Enrollment

3

Participants

Timeline

Start Date

April 12, 2022

Primary Completion Date

February 1, 2023

Study Completion Date

February 1, 2023

Conditions
Ovarian Cancer
Interventions
DRUG

mesothelin-specific chimeric antigen receptor T cell injection

Autologous T cell injection

Trial Locations (1)

Unknown

First affiliated hospital, School of Medicine, Zhejiang University, Hangzhou

All Listed Sponsors
collaborator

Nanjing Blue Shield Biotech Co.,Ltd

UNKNOWN

lead

Weijia Fang, MD

OTHER